Repebody for novel interleukin-6 and use thereof
US10017570B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Feb 27, 2013 |
| Grant date | Jul 10, 2018 |
| Priority date | — |
| Expiry date | Feb 1, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/73
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of signal transduction and activator of transciption3 (STAT3) and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.